SUPLEXA, a multimodal autologous cellular therapy, shows immunomodulatory behavior in cancer patients consistent with improved anti-tumor immune function.
Authors: J Pulford, E Murzin, D Younger, R Joshi, JC Goh, G Kichenadasse, SE Gargosky, F Borriello, and J Lederer.
Topline safety and efficacy update of SUPLEXA-101, a First-in-Human, Single Agent Study of SUPLEXA Therapeutic Cells in 28 Patients with Metastatic Solid Tumors.
Authors: R Joshi, JC Goh, G Kichenadasse, V Atkinson, W Joubert, V Kwatra, M Okera, S Bishnoi, G Nisyrios, J Lederer, SE.
To request interviews, high res images or other materials, media are asked to:
Email: media@alloplexbio.com
Attn: Lesley White, Alloplex Australia
For media requests on deadline during USA Eastern hours, please call: +1-781-281-2013
